Replimune Group Overview
Latest P/B ratio for Replimune Group: 13.07 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow13.07
The Price-to-Book ratio compares a company's market value to its book value. A lower P/B ratio may suggest that the stock is undervalued relative to its assets.
Replimune Group (REPL) currently reports a P/B ratio of 13.07. That is above the Healthcare sector average of 6.17. Use the charts on this page to explore Replimune Group's P/B ratio history and peer comparisons.
Replimune Group's P/B ratio of 13.07 is higher than the Healthcare sector average of 6.17. That is roughly 111.8% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/B ratio is a valuation multiple that relates Replimune Group's market price to a fundamental measure such as earnings, sales, or book value. At 13.07, REPL can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/B ratio of 13.07, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 6.17. From there, open related valuation or income-statement pages for Replimune Group, and consider following REPL for alerts when major investors trade the stock.
Replimune Group is classified in the Healthcare sector. On P/B ratio, it currently shows 13.07 versus a sector average near 6.17. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing REPL with unrelated industries.
